Efficacy of Oral Nano-Silymarin Formulation in the Prevention of Bone Marrow Suppression Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer
-
Hedyieh Karbasforooshan
,
Hossein Rahimi
,
Omid Arasteh
,
Abolghasem Allahyari
,
Mehdi Varmaghani
,
Sepideh Elyasi
Abstract
Background: Bone marrow suppression (BMS) is one of the main complications of chemotherapeutic agents. Given its anti-inflammatory, anti-oxidant, and anti-apoptotic properties, silymarin, a flavonoid derived from Silybum marianum, has been used against chemotherapy-induced BMS. The purpose of this research was to elucidate the advantages of oral nano-silymarin as a supplement to XELOX (oxaliplatin and capecitabine) or m-FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) regimen in relieving BMS in patients with metastatic colorectal cancer.
Methods: A clinical trial was conducted on 60 individuals through a randomized, triple-blinded, placebo-controlled design. The participants received 70 mg capsules with 15% silymarin nano micelles or placebo capsules, twice daily after meals for the duration of six courses of XELOX or m-FOLFOX6, starting from the first day of treatment. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5 was applied to evaluate the grade of BMS following the third and sixth chemotherapy cycles.
Results: The nano-silymarin group had significantly lower median CTCAE scores for both thrombocytopenia and neutropenia at the end of the third course (P<0.001). However, the difference remained significant only for neutropenia at the end of the sixth course (P<0.001). On the other hand, nano-silymarin did not have protective effects against anemia. Moreover, based on the frequency of CTCAE grading scores, the differences remained significant until the end of the study for thrombocytopenia and neutropenia, but just until the end of the third course for anemia.
Conclusion: Nano-silymarin may display preventive effects against chemotherapy-induced bone marrow suppression, particularly neutropenia and thrombocytopenia in patients with metastatic colorectal cancer. However, further studies with larger sample sizes are required.
Farashi E, Mahmoodpour A, Akbari AM, Sanaat Z, Sarbakhsh P, Chavoshi SH, et al. An Investigation of Insulin Resistance and Cachexia Relation in Patients with Metastatic Gastrointestinal Malignancies. J Pharm Care. 2022;10(4):195-204.
Dosunmu GT, Shergill A. Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine. Genes (Basel). 2024;15(5):538.
Salehifar E, Gheibi Sh, Janbabaei Gh, Mousavi Kh. Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran, 2008-2014. J Pharm Care 2016; 4(1-2): 9-13.
Morris VK, Kennedy EB, Baxter NN, Benson III AB, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678-700.
Underwood PW, Ruff SM, Pawlik TM. Update on targeted therapy and immunotherapy for metastatic colorectal cancer. Cells. 2024;13(3):245.
Ferro Y, Maurotti S, Tarsitano MG, Lodari O, Pujia R, Mazza E, et al. Therapeutic Fasting in Reducing Chemotherapy Side Effects in Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(12):2666.
Sharma U, Sahni PK, Sharma B, Gupta M, Kaur D, Mathkor DM, et al. Silymarin: a promising modulator of apoptosis and survival signaling in cancer. Discov Oncol. 2025;16(1):66.
Surai PF, Surai A, Earle-Payne K. Silymarin and Inflammation: Food for Thoughts. Antioxidants (Basel). 2024;13(1):98.
Gholami AH, Ansari H, Dadkhah A. Effect of Silybum Marianum on Reduction of Chemotherapy-Induced Peripheral Neurotoxicity with Cisplatin. Adv Biomed Res. 2024;13:21.
Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother Res. 2019;33(6):1627-38.
Dhande D, Dhok A, Anjankar A, Nagpure S. Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review. Cureus. 2024;16(8):e67083.
Mohebbati R, Momeni-Moghaddam MA, Asghari R, Abbasnezhad A, Bideskan AEZ, Salarbashi D, et al. The comparison of the effects of nano-silymarin and silymarin on high-fat diet-induced fatty liver of adult male rats. Avicenna J Phytomed. 2024;14(3):365-75.
Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: Types, properties and applications in drug delivery. IET nanobiotechnol. 2021;15(1):19-27.
Arab FL, Yousefi F, Jaafari MR, Rajabian A, Dana H, Tabasi N, et al. Evaluation of the immune-modulatory, anti-oxidant, proliferative, and anti-apoptotic effects of nano-silymarin on mesenchymal stem cells isolated from multiple sclerosis patients' adipose tissue sources. J Funct Foods. 2024;113:105958.
Mombeini M, Saki G, Khorsandi L, Bavarsad N. Effects of silymarin-loaded nanoparticles on HT-29 human colon cancer cells. Medicina (Kaunas). 2018;54(1):1.
Li X, Yuan Q, Huang Y, Zhou Y, Liu Y. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. Aaps Pharmscitech. 2010;11(2):672-8.
Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules. 2019;24(11):2155.
Karbasforooshan H, Rahimi H, Arasteh O, Allahyari A, Varmaghani M, Jannati M, et al. Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial. Iran J Pharm Res: IJPR. 2024;23(1):e152364.
Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006;12(9):2944-50.
Koltai T, Fliegel L. Role of silymarin in cancer treatment: facts, hypotheses, and questions. J Evid Based Integr Med. 2022;27:2515690X211068826.
Koushki M, Yekta RF, Amiri-Dashatan N. Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid. J Funct Foods. 2023;104:105502.
Exir Nano Sina. Sinaliv 70 [Internet]. Iran: Exir Nano Sina. Available from: https://ens.co.ir/products.
Guo Y, Xiong B-H, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Cancer invest. 2016;34(2):94-104.
U.S. Department of Health and Human Services [Internet]. Common terminology criteria for adverse events (CTCAE) v 5.0; 2017 [cited 2025 Oct 05]. Available from: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf
Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057-73.
Abbasinia H, Heshmati M, Yousefi M, Najjar N, Sadeghi H. Silymarin-loaded tin(IV) nanoparticles exhibit enhanced bioavailability and antiproliferative effects on colorectal cancer cells. ACS Appl Bio Mater. 2023;6(9):3768-77.
Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev. 2022;109:102427.
Xiao AT, Tong YX, Xu XS, Zhou Y, Zhang S. Preoperative nutritional status contributes to the development of neutropenia event in patients with gastric cancer receiving CAPEOX adjuvant chemotherapy. Front Oncol. 2020;10:692.
Phua VCE, Wong WQ, Tan PL, Bustam AZ, Saad M, Alip A, et al. Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice. Asian Pac J Cancer Prev. 2015;16(4):1449-53.
Khan M, Alharbi S, Aljuhani S, Tunkar M, Morya A, Alnatsheh A, et al. The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center. Cureus. 2023;15(8):e44267.
Ghazanfar H, Nawaz I, Ali N. Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms. Cureus. 2020;12(8):e9929.
Lees JG, White D, Keating BA, Barkl-Luke ME, Makker PG, Goldstein D, et al. Oxaliplatin-induced haematological toxicity and splenomegaly in mice. Plos one. 2020;15(9):e0238164.
Gao A, Zhang L, Zhong D. Chemotherapy-induced thrombocytopenia: literature review. Discov Oncol. 2023;14(1):10.
Kato N, Nakai T, Kodama S, Koyama S, Nakane S, Wada Y, et al. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer. in vivo. 2024;38(3):1243-52.
Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology. 2014;30(2):55-65.
Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020;145:102837.
Cobo F, De Celis G, Pereira A, Latorre X, Pujadas J, Albiol S. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anticancer drugs. 2007;18(8):973-6.
Sideris S, Loizidou A, Georgala A, Lebrun F, Gil T, Awada P, et al. Autoimmune haemolytic anaemia in a patient treated with capecitabine. Acta Clin Belg. 2013;68(2):135-7.
Yunan T, Yuke X, Guoran W, Dong W, Huifeng Z, Tao W, et al. Effects and mechanisms of Bazhen decoction, Siwu decoction, and Sijunzi decoction on 5-fluorouracil-induced anemia in mice. J Tradit Chin Med. 2016;36(4):486-95.
Salem S, Abd El-Baky A, Mohammed F. Cytoprotective effect of silymarin on cisplatin induced hepatotoxicity and bone marrow toxicity in rats. Asian J Anim Sci. 2017;11(3):140-152.
Ferraz AC, Almeida LT, da Silva Caetano CC, da Silva Menegatto MB, Lima RLS, de Senna JPN, et al. Hepatoprotective, antioxidant, anti-inflammatory, and antiviral activities of silymarin against mayaro virus infection. Antiviral Res. 2021;194:105168.
Baghbahadorani FK, Miraj S. The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia. Electron Physician. 2016;8(5):2436-42.
| Issue | Vol 13, No 3 (Summer 2025) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v13i3.20318 | |
| Keywords | ||
| XELOX m-FOLFOX6 Nano-Silymarin Metastatic Colorectal Cancer Bone Marrow Suppression | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
